The unified social credit code/registration number of Jilin Shilong Pharmaceutical Group Co., Ltd. is 9122010367 73087794, and Shao is an enterprise legal person. At present, the enterprise is in the state of opening.
The business scope of Jilin Shilong Pharmaceutical Group Co., Ltd. is: research and development of medical devices; 220 common diagnostic instruments 226 physiotherapy rehabilitation equipment 3 15 injection puncture instruments 32 1 medical electronic instruments 322 medical optical instruments, instruments and endoscopic equipment 354 operating room, emergency room, outpatient equipment and instruments 366 medical polymer materials and products 264 medical sanitary materials and dressings, 346 implant materials and artificial organs, 377 interventional instruments disposable sterile medical instruments (wholesale) (license validity) Acquisition of Chinese herbal medicines (except for projects requiring special approval); Slicing Ginseng Radix, packaging, and making into whiskers; Plaster production, processing, and sales (the health permit for health care product production enterprises is valid until 2016165438+129 October) and liquid disinfectant production (the health permit for disinfection products production enterprises is valid until 201April 15 October); Processing and marketing of health food; Production, processing and sales of velvet antler products; Food production, processing and sales (except for special approval and licensed operation, enterprises may not operate without permission). (Projects subject to approval according to law can only be operated after approval by relevant departments). In Jilin Province, the total registered capital of companies with similar business scope is 398.05 million yuan, and the main capital is concentrated in enterprises with scale of 50 million and above 10000-5000000, with 17. In the province, the registered capital of enterprises is excellent.
See more information and materials of Jilin Shilong Pharmaceutical Group Co., Ltd. through Baidu Enterprise Credit.